Xiaoke Pill lowered hypoglycemia risk with similar HbA1c control
Last updated May 6, 2026
Key finding
In adults with type 2 diabetes and poor glycemic control, Xiaoke Pill lowered hypoglycemia risk compared with glibenclamide while delivering similar HbA1c improvement over 48 weeks.
This multicenter trial compared Xiaoke Pill, a traditional Chinese medicine compound containing low-dose glibenclamide, with glibenclamide alone in 800 adults with type 2 diabetes. Over 48 weeks, both treatments improved HbA1c and fasting glucose similarly, but Xiaoke Pill caused fewer hypoglycemia episodes, especially in drug-naive patients and in people already taking metformin.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
Randomized Controlled Trials (RCTs)
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
In adults with type 2 diabetes and poor glycemic control, Xiaoke Pill lowered hypoglycemia risk compared with glibenclamide while delivering similar HbA1c improvement over 48 weeks.
Published in
Journal Reference
Publication details and source links for this paper.
Ji L, Tong X, Wang H, et al; Evidence-Based Medical Research of Xiaoke Pill Study Group. Efficacy and Safety of Traditional Chinese Medicine for Diabetes: A Double-Blind, Randomised, Controlled Trial. PLoS One. 2013;8(2):e56703. doi:10.1371/journal.pone.0056703
Main Effects
Hypoglycemia events ↓ with Xiaoke Pill compared with glibenclamide
HbA1c ↓ similarly in both treatment arms
Fasting plasma glucose ↓ similarly in both treatment arms
Serious adverse events ↔ none were reported
Evidence Suggest
- In the drug-naive group, Xiaoke Pill lowered the odds of any hypoglycemia by 38% and mild hypoglycemia by 41% versus glibenclamide.
- In the metformin group, Xiaoke Pill lowered the annual hypoglycemia rate by 62% compared with glibenclamide.
- HbA1c fell by 0.70% with Xiaoke Pill and 0.66% with glibenclamide in the drug-naive group, and by 0.45% versus 0.59% in the metformin group.
- No serious adverse event was reported during the 48-week trial.
Who this applies to
These findings apply most directly to adults aged 21 to 70 with type 2 diabetes, poor glycemic control, and either no prior glucose-lowering drugs or stable metformin use. The results are less certain for non-Chinese populations, people with advanced complications, or those using insulin or other modern drug combinations.
Keep in Mind
Xiaoke Pill was compared with glibenclamide alone, not with newer diabetes treatments. The trial supports similar glucose lowering and fewer hypoglycemia episodes, but it does not prove that the herbal components improve long-term complications. Treatment decisions should still consider access, safety monitoring, and whether sulfonylurea therapy is appropriate in the first place.
Between the Lines
- All participants were treated in China, so generalizability may be limited.
- The study used an active comparator, not a placebo-only herbal control.
- Xiaoke Pill already contains glibenclamide, so the herbal effect cannot be isolated fully.
- Some secondary outcomes were subgroup-based or not fully detailed in the main text.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.